Tempus AI's first quarter 2026 revenue grew 36% as the company raises full-year guidance.

Tempus AI reported first quarter 2026 revenue of $348.1 million, an increase of 36.1% year-over-year, driven by strong performance in both its Diagnostics and Data segments. The company reported a GAAP Net Loss of ($125.9 million) and an Adjusted EBITDA of ($2.8 million), an improvement from ($16.2 million) in the prior year period. Tempus raised its full-year 2026 revenue guidance.

Key Highlights

• Data and Applications revenue accelerated, growing 40.5% YoY to $87.0 million, with the Insights data licensing business growing 44.1%.
• Diagnostics revenue grew 34.7% YoY to $261.1 million, supported by a 28% increase in Oncology test volume.
• Volume for the company's newer MRD (Minimal Residual Disease) tests saw significant traction, growing approximately 500% year-over-year to roughly 6,500 tests.
• Tempus raised its full-year 2026 revenue guidance to a range of $1.59 billion to $1.60 billion, while reiterating its expectation for approximately $65 million in Adjusted EBITDA.